Nivolumab in NSCLC: latest evidence and clinical potential
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
Source: Therapeutic Advances in Medical Oncology - Category: Cancer & Oncology Authors: Sundar, R., Cho, B.-C., Brahmer, J. R., Soo, R. A. Tags: Reviews Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Skin Cancer | Study